Takeaways: Leqembi’s positive reimbursement step in Canada is a meaningful commercial win because it could unlock public coverage for the first disease-modifying Alzheimer’s therapy in the count...
Takeaways Sobi’s Empaveli is now positioned to move from import‑only, limited‑access status into publicly funded, pan‑Canadian treatment for C3 glomerulopathy and primary IC‑MPGN, one ...
Takeaways Ebglyss is now positioned to move from province‑specific coverage into broad, pan-Canadian reimbursement, which should materially expand Lilly’s eczema market and patient access. ...
Takeaways: Quebec’s listing of PrOKEDI on the RAMQ formulary is a key commercial milestone for Bausch Health, turning a specialized, once‑monthly long‑acting risperidone into a publicl...
Takeaways: Cipher’s pCPA LOI for Epuris is a market inflection point that should expand revenue and prescription volume by shifting isotretinoin from patchy, private-pay cove...
For most of modern medicine, the pharmaceutical industry has operated largely within a reactive healthcare model, developing therapies designed to treat diseases after they emerge. Today, however, adv...
Takeaways: Roche’s pCPA win for Itovebi is a major reimbursement de-risking event in Canada, because it moves the drug much closer to broad public coverage after a ...
Takeaways: The positive recommendation from CDA-AMC, backed by Phase III BE HEARD I and II trials, should accelerate payer negotiations and improve access for patients with chronic, pa...
The world’s population is aging at an unprecedented pace, creating one of the most significant long term shifts in global healthcare demand. By the coming decades, older adults will represent an incre...
Takeaways: BeOne Medicines has cleared the key reimbursement hurdles in Canada for Tevimbra + gemcitabine/cisplatin as the first publicly funded first-line immunotherapy for recurrent/metastatic...
